Associated Papers
CYP genetic polymorphism, and CYP3A inducers and inhibitors regulate apatinib metabolism: Consequences for drug exposure and toxicity risks.
Wang Z et al.
Toxicology and Applied Pharmacology, 2026
Differential metabolism of citalopram by 21 CYP3A4 variants: An in vitro experiment.
Wang P et al.
Journal of Psychopharmacology (oxford, England), 2025
An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.
Sychev DA et al.
Pharmaceuticals (basel, Switzerland), 2025
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored.
Mwaniki RM et al.
Journal of Molecular Biology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients.
Bouafia M et al.
Molecular Biology Reports, 2025
Inhibition Mechanism of Ketamine-Apatinib by CYP2C9 and 3A4: A Prediction of Possible Drug-Drug Interaction.
Zheng X et al.
Biopharmaceutics & Drug Disposition, 2025
CYP3A4 activity variations can lead to stratified metabolism of abemaciclib.
Xu XY et al.
International Journal of Biological Macromolecules, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.
Wang CC et al.
Biomedical Chromatography : Bmc, 2025
Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
Shoji K et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Identification and Functional Assessment of Eight CYP3A4 Allelic Variants *39-*46 Detected in the Chinese Han Population.
Qi Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population.
Hu X et al.
Peerj, 2024
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.
Zhang X et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism.
Yuan LJ et al.
Toxicology and Applied Pharmacology, 2023
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2023
CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy.
Wang F et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Maekawa K et al.
Drug Metabolism and Pharmacokinetics, 2022
Pharmacogenetics of Drugs Used in the Treatment of Cancers.
Franczyk B et al.
Genes, 2022
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.
Yoon JG et al.
Transplantation, 2021
A MT-TL1 variant identified by whole exome sequencing in an individual with intellectual disability, epilepsy, and spastic tetraparesis.
de Boer E et al.
European Journal of Human Genetics : Ejhg, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.
Fohner AE et al.
Clinical and Translational Science, 2021
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients.
Satapornpong P et al.
Frontiers in Immunology, 2021
Impact of Cilostazol Pharmacokinetics on the Development of Cardiovascular Side Effects in Patients with Cerebral Infarction.
Yokoyama T et al.
Biological & Pharmaceutical Bulletin, 2021
Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients.
Miranda C et al.
Frontiers in Pharmacology, 2021
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Paulík A et al.
Tumori, 2020
Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B et al.
Chemical Research in Toxicology, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related.
Guttman Y et al.
Frontiers in Genetics, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
Lee HI et al.
European Journal of Clinical Pharmacology, 2018
Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution.
Arendse LB et al.
Scientific Reports, 2018
The potential role of pharmacogenomics and biotransformation in hypersensitivity reactions to paracetamol.
Agúndez JAG et al.
Current Opinion in Allergy and Clinical Immunology, 2018
Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro.
Fang P et al.
Drug Design, Development and Therapy, 2017
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N et al.
Meta Gene, 2016
Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.
Jarrar M et al.
Molecular Biology Reports, 2016
Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications.
Creemer OJ et al.
Pharmacogenetics and Genomics, 2016